{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:16:03Z","timestamp":1791292563544,"version":"4.1.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,7,7]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Low-dose IL-2 is efficacious in steroid-refractory cGVHD, with objective responses in &gt;50% of patients, and durable disease control. IL-2 initiation earlier after cGVHD onset, prior to severe impairment of Treg:Tcon ratios, improves likelihood of clinical response.<\/jats:p>","DOI":"10.1182\/blood-2016-02-702852","type":"journal-article","created":{"date-parts":[[2016,4,13]],"date-time":"2016-04-13T03:23:17Z","timestamp":1460517797000},"page":"130-137","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":205,"title":["Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease"],"prefix":"10.1182","volume":"128","author":[{"given":"John","family":"Koreth","sequence":"first","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesook T.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle T.","family":"Jones","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina B.","family":"Lange","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol G.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie J.","family":"Chammas","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Dusenbury","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Whangbo","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nikiforow","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Edwin P.","family":"Alyea","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey S.","family":"Cutler","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Avigan","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Blazar","sequence":"additional","affiliation":[{"name":"University of Minnesota Masonic Cancer Center and Division of Blood and Marrow Transplantation, Department of Pediatrics, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"17","key":"2019111903002306400_B1","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium.","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111903002306400_B2","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2014-01-514752","article-title":"Current issues in chronic graft-versus-host disease.","volume":"124","author":"Soci\u00e9","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111903002306400_B3","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","article-title":"How we treat chronic graft-versus-host disease.","volume":"125","author":"Flowers","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111903002306400_B4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.smim.2003.12.003","article-title":"Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance.","volume":"16","author":"Piccirillo","year":"2004","journal-title":"Semin Immunol"},{"issue":"2","key":"2019111903002306400_B5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.coi.2004.01.004","article-title":"Development and function of CD25+CD4+ regulatory T cells.","volume":"16","author":"Feh\u00e9rvari","year":"2004","journal-title":"Curr Opin Immunol"},{"issue":"15","key":"2019111903002306400_B6","first-page":"4516","article-title":"Human CD4+ CD25+ regulatory T cells suppress NKT cell functions.","volume":"63","author":"Azuma","year":"2003","journal-title":"Cancer Res"},{"issue":"6","key":"2019111903002306400_B7","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/1521-4141(200006)30:6<1538::AID-IMMU1538>3.0.CO;2-X","article-title":"CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells.","volume":"30","author":"Cederbom","year":"2000","journal-title":"Eur J Immunol"},{"issue":"1","key":"2019111903002306400_B8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1084\/jem.20021345","article-title":"CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms.","volume":"197","author":"Maloy","year":"2003","journal-title":"J Exp Med"},{"issue":"6","key":"2019111903002306400_B9","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1074-7613(03)00327-3","article-title":"CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells.","volume":"19","author":"Serra","year":"2003","journal-title":"Immunity"},{"issue":"2","key":"2019111903002306400_B10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1084\/jem.188.2.287","article-title":"CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.","volume":"188","author":"Thornton","year":"1998","journal-title":"J Exp Med"},{"issue":"9","key":"2019111903002306400_B11","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.4049\/jimmunol.171.9.4604","article-title":"CD4+CD25+ T cells lyse antigen-presenting B cells by Fas-Fas ligand interaction in an epitope-specific manner.","volume":"171","author":"Janssens","year":"2003","journal-title":"J Immunol"},{"issue":"8","key":"2019111903002306400_B12","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1182\/blood-2005-03-1257","article-title":"Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.","volume":"106","author":"Zorn","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2019111903002306400_B13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1172\/JCI41072","article-title":"Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.","volume":"120","author":"Matsuoka","year":"2010","journal-title":"J Clin Invest"},{"issue":"12","key":"2019111903002306400_B14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nri2889","article-title":"Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases.","volume":"10","author":"Buckner","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2019111903002306400_B15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1084\/jem.20020399","article-title":"Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.","volume":"196","author":"Hoffmann","year":"2002","journal-title":"J Exp Med"},{"issue":"10","key":"2019111903002306400_B16","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.V99.10.3493","article-title":"The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.","volume":"99","author":"Taylor","year":"2002","journal-title":"Blood"},{"issue":"9","key":"2019111903002306400_B17","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nm915","article-title":"CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.","volume":"9","author":"Edinger","year":"2003","journal-title":"Nat Med"},{"issue":"9","key":"2019111903002306400_B18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri1435","article-title":"Tolerance, not immunity, crucially depends on IL-2.","volume":"4","author":"Malek","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"2019111903002306400_B19","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.4049\/jimmunol.172.7.3983","article-title":"IL-2, regulatory T cells, and tolerance.","volume":"172","author":"Nelson","year":"2004","journal-title":"J Immunol"},{"issue":"22","key":"2019111903002306400_B20","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease.","volume":"365","author":"Koreth","year":"2011","journal-title":"N Engl J Med"},{"issue":"179","key":"2019111903002306400_B21","doi-asserted-by":"crossref","first-page":"179ra43","DOI":"10.1126\/scitranslmed.3005265","article-title":"Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.","volume":"5","author":"Matsuoka","year":"2013","journal-title":"Sci Transl Med"},{"issue":"12","key":"2019111903002306400_B22","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111903002306400_B23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bbmt.2006.01.008","article-title":"Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.","volume":"12","author":"Pavletic","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111903002306400_B24","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2019111903002306400_B25","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/bbmt.2002.v8.pm12234170","article-title":"Development and validation of a scale to measure symptoms of chronic graft-versus-host disease.","volume":"8","author":"Lee","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111903002306400_B26","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of k-sample tests for comparing the cumulative incidence of a competing risk.","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"24","key":"2019111903002306400_B27","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2014-07-587493","article-title":"Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy.","volume":"124","author":"Van Gool","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111903002306400_B28","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood"},{"issue":"14","key":"2019111903002306400_B29","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation.","volume":"117","author":"Di Ianni","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111903002306400_B30","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2015-06-653667","article-title":"Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.","volume":"127","author":"Brunstein","year":"2016","journal-title":"Blood"},{"key":"2019111903002306400_B31","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2014.50","article-title":"Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.","volume-title":"Mol Ther","author":"Ito","year":"2014"},{"key":"2019111903002306400_B32","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-13-3205","article-title":"Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.","volume-title":"Clin Cancer Res","author":"Kennedy-Nasser","year":"2014"},{"issue":"22","key":"2019111903002306400_B33","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.","volume":"365","author":"Saadoun","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111903002306400_B34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial.","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2019111903002306400_B35","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/annrheumdis-2014-206506","article-title":"Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE.","volume":"74","author":"Humrich","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2019111903002306400_B36","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","article-title":"Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata.","volume":"150","author":"Castela","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"13","key":"2019111903002306400_B37","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1182\/blood-2012-04-424135","article-title":"Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.","volume":"120","author":"Jacobsohn","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111903002306400_B38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/bmt.2013.107","article-title":"Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice [published correction appears in Bone Marrow Transplant. 2014;49(2):319].","volume":"49","author":"Ruutu","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2019111903002306400_B39","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.bbmt.2012.05.005","article-title":"Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease.","volume":"18","author":"Palmer","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"2019111903002306400_B40","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2013-05-494278","article-title":"Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD.","volume":"122","author":"Olivieri","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111903002306400_B41","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3324\/haematol.2014.117283","article-title":"Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease.","volume":"100","author":"Palmer","year":"2015","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/1\/130\/1395501\/130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/1\/130\/1395501\/130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T08:01:22Z","timestamp":1574150482000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/1\/130\/35356\/Efficacy-durability-and-response-predictors-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,7]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-02-702852","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,7]]}}}